الإحصائيات الأساسية
| LEI | 5493009HV8O6R1WGZ132 |
| CIK | 1017491 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Seelos Therapeutics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| February 14, 2025 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Seelos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to su |
|
| December 4, 2024 |
SEEL / Seelos Therapeutics, Inc. / AdvisorShares Trust Passive Investment SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Seelos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81577F406 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to de |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| November 22, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Seelos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to su |
|
| November 14, 2024 |
SEEL / Seelos Therapeutics, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Seelos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81577F406 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| November 5, 2024 |
SEEL / Seelos Therapeutics, Inc. / AdvisorShares Trust Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Seelos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81577F406 (CUSIP Number) October 31, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to design |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy S |
|
| October 24, 2024 |
Seelos Announces Second Postponement of its Annual Meeting of Stockholders Exhibit 99.1 Seelos Announces Second Postponement of its Annual Meeting of Stockholders NEW YORK, October 24, 2024 /PRNewswire/ - Seelos Therapeutics, Inc. (OTCQB: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeti |
|
| October 24, 2024 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 15, 2024 |
Exhibit 99.1 Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market NEW YORK, October 15, 2024 – Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on October 14, |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 26, 2024 |
Seelos Announces Postponement of its Annual Meeting of Stockholders Exhibit 99.1 Seelos Announces Postponement of its Annual Meeting of Stockholders NEW YORK, September 26, 2024 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| September 25, 2024 |
As filed with the Securities and Exchange Commission on September 24, 2024 As filed with the Securities and Exchange Commission on September 24, 2024 Registration No. |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 25, 2024 |
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split Exhibit 99.1 Seelos Therapeutics Announces 1-for-16 Reverse Stock Split NEW YORK, September 25, 2024 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-16 reverse sto |
|
| September 25, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Seelos Therapeutics, Inc. |
|
| September 25, 2024 |
Exhibit 3.1 |
|
| September 24, 2024 |
Exhibit 99.1 Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD -Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK, September 24, 2024 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company foc |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 3, 2024 |
Exhibit 10.1 AGREEMENT This AGREEMENT (the “Agreement”) is made as of the 30 day of August, 2024, by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC (the “Investor”). WHEREAS, on November 23, 2021, the Company and the Investor entered into a Securities Purchase Agreement, as amended (the “Purchase Agreement”), pursuant to which t |
|
| August 22, 2024 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 August 22, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Daniel Crawford Re: Seelos Therapeutics, Inc. Registration Statement on Form S-3 Filed August 16, 2024 File No. 333-281604 Ladies and Gentlemen: Seelos Therapeutics, Inc. (the |
|
| August 20, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Seelos Therapeutics, Inc. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-2 |
|
| August 9, 2024 |
TABLE OF CONTENTS PRELIMINARY COPY DATED AUGUST 9, 2024 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 16, 2024 |
Exhibit 4.1 AMENDMENT NO. 8 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 8 to Convertible Promissory Note (this “Amendment”) is effective as of July 16, 2024 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, the |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 12, 2024 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 12, 2024 |
Exhibit 10.1 SEELOS THERAPEUTICS, INC. July 11, 2024 Holder of Warrants Issued in December 2023 and January 2024 Re: Inducement Offer to Exercise Warrants Issued in December 2023 and January 2024 Dear Holder: Seelos Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase shares of the Company’s commo |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 25, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280215 PROSPECTUS 924,414 Shares Common Stock This prospectus relates to the resale by the investors listed in the section of this prospectus entitled “Selling Stockholders” (the “Selling Stockholders”), of up to 924,414 shares (the “Shares”) of our common stock, par value $0.001 per share (“Common Stock”). The 924,414 sha |
|
| June 21, 2024 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 June 21, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-280215 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutics, Inc. (the “Company”) hereby r |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Seelos Therapeutics, Inc. |
|
| June 5, 2024 |
Exhibit 4.1 AMENDMENT NO. 7 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 7 to Convertible Promissory Note (this “Amendment”) is effective as of June 1, 2024 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, the “ |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 21, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT seelos therapeutics, inc. Warrant Shares: Issue Date: May 21, 2024 Initial Exercise Date: May 21, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| May 21, 2024 |
Form of Securities Purchase Agreement, dated May 16, 2024. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2024, between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| May 21, 2024 |
Placement Agency Agreement, dated May 16, 2024. Exhibit 10.2 PLACEMENT AGENCY AGREEMENT May 16, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $1,137,029.22 of registered and unregistered securitie |
|
| May 21, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 20, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276119 PROSPECTUS SUPPLEMENT (to Prospectus dated December 27, 2023) 380,968 Shares of Common Stock Pre-Funded Warrants to Purchase 81,239 Shares of Common Stock Up to 81,239 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering directly to investors 380,968 shares of our common stock, $0.001 par value pe |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 16, 2024 |
Exhibit 3.1 Filed in the Office of Secretary of State State Of Nevada Business Number C8119-1987 Filing Number 20244061253 Filed On 5/15/2024 8:18:00 AM Number of Pages 1 |
|
| May 14, 2024 |
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split Exhibit 99.1 Seelos Therapeutics Announces 1-for-8 Reverse Stock Split NEW YORK, May 14, 2024 – Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its outst |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000- |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 3, 2024 |
Exhibit 4.1 AMENDMENT NO. 6 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 6 to Convertible Promissory Note (this “Amendment”) is effective as of May 1, 2024 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEEL |
|
| March 28, 2024 |
Exhibit 4.1 AMENDMENT NO. 5 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 5 to Convertible Promissory Note (this “Amendment”) is effective as of March 27, 2024 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited liability company (together with its successors and representatives, the |
|
| March 28, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 19, 2024 |
Exhibit 99.2 SEELOS THERAPEUTICS SLS - 005 ALS Top - Line Data March 2024 “We are a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases” FORWARD - LOOKING STATEMENTS This corporate presentation includes certain forward - looking statements within the meaning of Section 21E of the Securities Exch ange Act |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 19, 2024 |
Exhibit 99.1 Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) NEW YORK, March 19, 2024 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an up |
|
| March 15, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276831 PROSPECTUS 3,404,256 Shares Common Stock This prospectus relates to the resale by the investors listed in the section of this prospectus entitled “Selling Stockholders” (the “Selling Stockholders”), of up to 3,404,256 shares (the “Shares”) of our common stock, par value $0.001 per share (“Common Stock”). The 3,404,256 |
|
| March 12, 2024 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 March 12, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-276831 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutics, Inc. (the “Compa |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Seelos Therapeutics, Inc. |
|
| March 6, 2024 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 VIA EDGAR CORRESP March 6, 2024 Daniel Crawford Laura Crotty United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-1 Filed February 2, 2024 File No. 333-276831 Dear Mr. Cra |
|
| March 6, 2024 |
Exhibit 4.6 DESCRIPTION OF SECURITIES OF SEELOS THERAPEUTICS, INC. The authorized capital stock of Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), consists of: · 400,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and · 10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). Common Stock · Voting Rights. Holders of Common |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEELOS T |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Seelos Therapeutics, Inc. Clawback Policy Exhibit 97 SEELOS THERAPEUTICS, INC. CLAWBACK POLICY The Board of Directors (the “Board”) of Seelos Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy |
|
| February 16, 2024 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 VIA EDGAR CORRESP February 16, 2024 Daniel Crawford Laura Crotty United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-1 Filed February 2, 2024 File No. 333-276831 Dear Mr. |
|
| February 6, 2024 |
US81577F2083 / SEELOS THERAPEUTICS INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Seelos Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81577F208 (CUSIP Number) January 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 6, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Seelos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to su |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Seelos Therapeutics, Inc. |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 30, 2024 |
Exhibit 10.2 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 January 26, 2024 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, New York 10022 Attention: Raj Mehra President, Chief Executive Officer and Chairman of the Board of Directors Re: Placement Agency Agreement Dear Mr. Mehra: Subject to the terms and conditions of this letter agreement (the “A |
|
| January 30, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 30, 2024 |
3,404,256 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-276119 PROSPECTUS SUPPLEMENT (to Prospectus dated December 27, 2023) 3,404,256 Shares of Common Stock We are offering directly to investors 3,404,256 shares of our common stock, $0.001 par value per share, at an offering price of $1.175 per share in a registered direct offering pursuant to this prospectus supplement and the |
|
| January 30, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 26, 2024, between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 22, 2024 |
Exhibit 99.1 Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 - Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults wi |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 10, 2024 |
Exhibit 3.1 Business Entity - Filing Acknowledgement 01/10/2024 Work Order Item Number: W2024011000383-3390553 Filing Number: 20243748592 Filing Type: Amendment After Issuance of Stock Filing Date/Time: 1/10/2024 8:50:00 AM Filing Page(s): 2 Indexed Entity Information: Entity ID: C8119-1987 Entity Name: SEELOS THERAPEUTICS, INC. Entity Status: Active Expiration Date: None Commercial Registered Age |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| December 21, 2023 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 December 21, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-3 Filed on December 18, 2023 Registration No. 333-276119 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Ther |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| December 18, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.15 Seelos Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| December 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Seelos Therapeutics, Inc. |
|
| December 18, 2023 |
As filed with the Securities and Exchange Commission on December 18, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 18, 2023 Registration No. |
|
| December 15, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| December 4, 2023 |
TABLE OF CONTENTS PRELIMINARY COPY DATED DECEMBER 4, 2023 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| December 1, 2023 |
Seelos Therapeutics Announces Closing of Public Offering Exhibit 99.1 Seelos Therapeutics Announces Closing of Public Offering NEW YORK, Dec. 1, 2023 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 1,781,934 sh |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 30, 2023 |
Exhibit 4.1 Form of Pre-funded Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: Issue Date: December 1, 2023 Initial Exercise Date: December 1, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and th |
|
| November 30, 2023 |
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering Exhibit 99.1 Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering NEW YORK, Nov. 28, 2023 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has priced its underwritten public offering of 1,781,934 shar |
|
| November 30, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2020) 1,781,934 Shares of Common Stock Pre-Funded Warrants to Purchase 2,422,612 Shares of Common Stock Common Warrants to Purchase 4,204,546 Shares of Common Stock We are offering 1,781,934 shares of our common stock, $0.001 par value per share, pre-funded warra |
|
| November 30, 2023 |
Exhibit 1.1 UNDERWRITING AGREEMENT between SEELOS THERAPEUTICS, INC. and TITAN PARTNERS GROUP LLC, A DIVISION OF AMERICAN CAPITAL PARTNERS, LLC as Representative of the Several Underwriters SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENT New York, New York November 28, 2023 Titan Partners Group, LLC, a division of American Capital Partners, LLC As Representative of the several Underwriters named |
|
| November 30, 2023 |
Exhibit 4.2 Form of Common Warrant COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: Issue Date: December 1, 2023 Initial Exercise Date: December 1, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 28, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-251356 SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED MAY 12, 2022 (To Prospectus dated December 23, 2020) Up to $50,000,000 Common Stock This Supplement No. 1 to Prospectus Supplement, or this Supplement No. 1, amends and supplements the information in the prospectus, dated December 23, 2020, or the Prospectus, and the prospectus supplement, |
|
| November 28, 2023 |
Exhibit 3.1 Business Entity - Filing Acknowledgement 11/27/2023 Work Order Item Number: W2023112700713-3299508 Filing Number: 20233653909 Filing Type: Certificate Pursuant to NRS 78.209 Filing Date/Time: 11/27/2023 9:32:00 AM Filing Page(s): 1 Indexed Entity Information: Entity ID: C8119-1987 Entity Name: SEELOS THERAPEUTICS, INC. Entity Status: Active Expiration Date: None Commercial Registered A |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 28, 2023 |
SUBJECT TO COMPLETION, DATED NOVEMBER 28, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 24, 2023 |
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split Exhibit 99.1 Seelos Therapeutics Announces 1-for-30 Reverse Stock Split NEW YORK, November 24, 2023 – Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-30 a reverse stock split of |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 24, 2023 |
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split Exhibit 99.1 Seelos Therapeutics Announces 1-for-30 Reverse Stock Split NEW YORK, November 24, 2023 – Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-30 a reverse stock split of |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 2, 2023 |
Exhibit 4.1 AMENDMENT NO. 4 TO CONVERTIBLE PROMISSORY NOTE AND AMENDMENT TO LETTER AGREEMENT This Amendment No. 4 to Convertible Promissory Note and Amendment to Letter Agreement (this “Amendment”) is effective as of September 30, 2023 (the “Effective Date”), by and between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and Lind Global Asset Management V, LLC, a Delaware limited |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 29, 2023 |
Seelos Therapeutics, Inc. 5,000,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-274533 PROSPECTUS Seelos Therapeutics, Inc. 5,000,000 Shares of Common Stock This prospectus relates to the resale by the investors listed in the section of this prospectus entitled “Selling Stockholders” (the “Selling Stockholders”) of up to 5,000,000 shares of our common stock, par value $0.001 per share (“Common Stock”). |
|
| September 26, 2023 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 September 26, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-3, Filed on September 15, 2023 File No. 333-274533 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeut |
|
| September 25, 2023 |
Exhibit 10.2 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 September 21, 2023 Lind Global Asset Management V, LLC c/o The Lind Partners LLC 444 Madison Avenue, Floor 41 New York, NY 10022 RE: Convertible Promissory Note 1. Note. Reference is hereby made to that certain Convertible Promissory Note No. 1, issued by Seelos Therapeutics, Inc., a Nevada corporation (the “Compa |
|
| September 25, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 21, 2023, between Seelos Therapeutics, Inc. a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| September 25, 2023 |
15,000,000 Shares of Common Stock Common Warrants to Purchase 10,010,010 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2020) 15,000,000 Shares of Common Stock Common Warrants to Purchase 10,010,010 Shares of Common Stock We are offering directly to investors 15,000,000 shares of our common stock, $0.001 par value per share (the “common stock”), and accompanying common stock warra |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 25, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September 25, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 20, 2023 |
Exhibit 99.1 Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide · SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality · Robust Response and Remission Rates were observed using the Montgomery-Åsberg Depression Rating Scale (MADRS) · Resu |
|
| September 20, 2023 |
Exhibit 99.2 SEELOS THERAPEUTICS September 2023 “We are a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases” FORWARD - LOOKING STATEMENTS This corporate presentation includes certain forward - looking statements within the meaning of Section 21E of the Securities Exch ange Act of 1934, as amended, and |
|
| September 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Seelos Therapeutics, Inc. |
|
| September 15, 2023 |
As filed with the Securities and Exchange Commission on September 15, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 15, 2023 Registration No. |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 14, 2023 |
Exhibit 99.1 IRREVOCABLE WAIVER Reference is hereby made to that certain Convertible Promissory Note No. 1, issued by Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), on November 23, 2021, as amended on December 10, 2021, February 8, 2023 and May 19, 2023 (as so amended, the “Note”), in the initial principal amount of $22,000,000 and due November 23, 2024, to Lind Global Asset Mana |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-2 |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 19, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 to SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to Securities Purchase Agreement (this “Amendment”) is dated as of May 19, 2023, among Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, t |
|
| May 19, 2023 |
EX-3.1 2 tm2316306d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 Business Entity - Filing Acknowledgement 05/18/2023 Work Order Item Number: W2023051801744-2916124 Filing Number: 20233206622 Filing Type: Amendment After Issuance of Stock Filing Date/Time: 5/18/2023 1:03:00 PM Filing Page(s): 2 Indexed Entity Information: Entity ID: C8119-1987 Entity Name: SEELOS THERAPEUTICS, INC. Entity Status: Active Expir |
|
| May 19, 2023 |
Exhibit 4.1 AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 (this “Amendment”) to that certain Convertible Promissory Note No. 1, issued on November 23, 2021, as amended on December 10, 2021 and on February 8, 2023 (as so amended, the “Note”), in the initial principal amount of $22,000,000 and due November 23, 2024, by Seelos Therapeutics, Inc., a Nevada corporation (the “Compa |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 19, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000- |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 12, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| March 31, 2023 |
TABLE OF CONTENTS PRELIMINARY COPY DATED MARCH 31, 2023 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 24, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SEELOS THERAPEUTICS, INC. ARTICLE I OFFICES Section 1.1. Principal Office. The principal office and place of business of Seelos Therapeutics, Inc. (the “Corporation”) shall be at 300 Park Avenue, 2nd Floor, New York, New York 10022, unless changed by the board of directors of the Corporation (the “Board of Directors” or “Board”). Section 1.2. Other Office |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 10, 2023, between Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: September 14, 2023 Issue Date: March 14, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| March 14, 2023 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: March 14, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| March 13, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2020) 12,059,298 Shares of Common Stock Pre-Funded Warrants to Purchase 9,340,702 Shares of Common Stock Common Warrants to Purchase 26,750,000 Shares of Common Stock We are offering directly to investors 12,059,298 shares of our common stock, $0.001 par value per share, pre-funded |
|
| March 10, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEELOS T |
|
| March 10, 2023 |
Exhibit 4.12 DESCRIPTION OF SECURITIES OF SEELOS THERAPEUTICS, INC. The authorized capital stock of Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), consists of: ● 240,000,000 shares of common stock, $0.001 par value per share (“Common Stock”); and ● 10,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). Common Stock ● Voting Rights. Holders of Common |
|
| March 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Seelos Therapeutics, Inc. |
|
| March 10, 2023 |
Exhibit 4.14 AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 (this “Amendment”) to that certain Convertible Promissory Note No. 1, issued on November 23, 2021, as amended on December 10, 2021 (as so amended, the “Note”), in the principal amount of $22,000,000 and due November 23, 2024, by Seelos Therapeutics, Inc., a Nevada corporation (the “Company”), to Lind Global Asset Mana |
|
| March 10, 2023 |
SEELOS THERAPEUTICS March 2023 “We are a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases” 1 Exhibit 99. |
|
| March 10, 2023 |
SUBSIDIARIES OF SEELOS THERAPEUTICS, INC. Exhibit 21.1 SUBSIDIARIES OF SEELOS THERAPEUTICS, INC. Name State or Jurisdiction of Incorporation or Organization NexMed (U.S.A.), Inc. Delaware Apricus Pharmaceuticals USA, Inc. Delaware NexMed Holdings, Inc. Delaware NexMed International Limited British Virgin Islands Seelos Corporation Delaware Seelos Therapeutics Australia Pty Ltd Australia |
|
| March 10, 2023 |
Exhibit 10.8 SEELOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (EFFECTIVE JANUARY 1, 2023) Non-employee members of the board of directors (the “Board”) of Seelos Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy. The cash compensation and option grants described in this Non- |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 9, 2023 |
SEEL / Seelos Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Seelos Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 81577F109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| November 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22245 SEELOS |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22245 SEELOS THER |
|
| May 23, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 12, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 12, 2022 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2020) Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, dated May 12, 2022, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In a |
|
| May 12, 2022 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM May 12, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Seelos Therapeutics, Inc., a Nevada corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common sto |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22245 SEELOS THE |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? ? ? De |
|
| April 22, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 12, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 11, 2022 |
Amendment No. 5 to Asset Purchase Agreement Exhibit 10.1 Amendment No. 5 to Asset Purchase Agreement This Amendment No. 5 (this ?Amendment?) to the Asset Purchase Agreement, dated as of March 6, 2018, by and between Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG, a stock corporation organized under the laws of Switzerland (?Seller?), and Seelos Corporation f/k/a Seelos Therapeutics, Inc., a Delaware corporation (? |
|
| April 11, 2022 |
Exhibit 99.1 Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee NEW YORK, April 11, 2022 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 4, 2022 |
Exhibit 4.22 AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This Amendment (this ?Amendment?) to that certain Convertible Promissory Note No. 1, issued on November 23, 2021 (the ?Note?), in the principal amount of $22,000,000 and due November 23, 2024, by Seelos Therapeutics, Inc., a Nevada corporation (the ?Company?), to Lind Global Asset Management V, LLC, a Delaware limited liability company (togethe |
|
| March 4, 2022 |
Description of Securities of Seelos Therapeutics, Inc. Exhibit 4.21 Description of Securities of Seelos Therapeutics, Inc. The authorized capital stock of Seelos Therapeutics, Inc., a Nevada corporation (the ?Company?), consists of: ? 240,000,000 shares of common stock, $0.001 par value per share (?Common Stock?); and ? 10,000,000 shares of preferred stock, $0.001 par value per share (?Preferred Stock?). Common Stock ? Voting Rights. Holders of Common |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEELOS THERAPEUTICS, INC |
|
| February 10, 2022 |
SEEL / Seelos Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Seelos Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 81577F109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| January 18, 2022 |
As filed with the Securities and Exchange Commission on January 18, 2022 As filed with the Securities and Exchange Commission on January 18, 2022 Registration No. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
Exhibit 10.1 SEELOS THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?), entered into as of January 10, 2022 (the ?Agreement Date?), is made by and between Seelos Therapeutics, Inc., a Nevada corporation (the ?Company?), and Raj Mehra, Ph.D. (?Executive? and together with the Company, the ?Parties?). This Agreement will bec |
|
| December 27, 2021 |
Seelos Therapeutics, Inc. 3,212,832 Shares of Common Stock 424B3 1 see424b3.htm 424(B)(3) PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261621 Seelos Therapeutics, Inc. 3,212,832 Shares of Common Stock This prospectus relates to the resale by the investor listed in the section of this prospectus entitled “Selling Stockholder” (the “Selling Stockholder”) of up to 3,212,832 shares (the “Shares”) of our common stock, par value $0.001 per s |
|
| December 22, 2021 |
Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, NY 10022 December 22, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-3, Filed on December 13, 2021 File No. 333-261621 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutic |
|
| December 13, 2021 |
As filed with the Securities and Exchange Commission on December 13, 2021 As filed with the Securities and Exchange Commission on December 13, 2021 Registration No. |
|
| November 24, 2021 |
Exhibit 10.2 SECURITY AGREEMENT SECURITY AGREEMENT (this "Agreement"), dated as of November 23, 2021, by and between SEELOS THERAPEUTICS, Inc., a Nevada corporation (the "Company") and LIND GLOBAL ASSET MANAGEMENT V, LLC (the "Secured Party"). WHEREAS, the Company (a) and the Secured Party have entered into that certain Securities Purchase Agreement dated as of the date hereof (as amended and in e |
|
| November 24, 2021 |
Exhibit 10.1 ***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[?***?]?) in this exhibit*** EXCLUSIVE LICENSE AGREEMENT This EXCLUSIV |
|
| November 24, 2021 |
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note Exhibit 99.1 Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note - Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones NEW YORK, Nov 24, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 24, 2021 |
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma?s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - New SLS-003 Program Extends Seelos? Ketamine Franchise into Additional Indications Including Chronic Neuropathic Pain and Additional Psychiatric Disorders - Program has been Granted Orphan Drug Designation in the US for the Treatment of Complex Regional Pain Syndrome NEW YORK, Nov. |
|
| November 24, 2021 |
Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| November 24, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this ?Agreement?) is entered into as of November 23, 2021, by and between Seelos Therapeutics, Inc., a Nevada corporation (the ?Company?), and Lind Global Asset Management V, LLC, a Delaware limited liability company (the ?Investor?). BACKGROUND A. Th |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 24, 2021 |
SEELOS THERAPEUTICS, INC. COMMON STOCK PURCHASE AGREEMENT Exhibit 10.2 ***Certain identified information has been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because it is both (i) not material to investors and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (?[?***?]?) in this exhibit*** SEELOS THERAPEUTICS, INC. COMMON STOCK PU |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22245 SEELOS |
|
| October 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 25, 2021 |
Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research - Data from the Part 1 Open-Label Portion of the Study Demonstrated a Rapid, Robust, and Sustained Improvement on all 4 Scales Utilized Measuring Depression and Suicide - Data Demonstrated the Group Mean Met the MADRS Responder Criteria at All Times Points M |
|
| September 2, 2021 |
Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors Exhibit 99.2 Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors NEW YORK, Sept. 2, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Margaret Dalesandro, Ph.D. to its Board o |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 2, 2021 |
Seelos Therapeutics Announces Senior Management Appointments Exhibit 99.1 Seelos Therapeutics Announces Senior Management Appointments NEW YORK, Sept. 1, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the promotions of Michael Golembiewski to Chief Financial Officer and Anthony Marciano to |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22245 SEELOS THER |
|
| June 17, 2021 |
ACKNOWLEDGMENT AND TERMINATION AGREEMENT Exhibit 10.1 ACKNOWLEDGMENT AND TERMINATION AGREEMENT THIS ACKNOWLEDGMENT AND TERMINATION AGREEMENT (this "Agreement") is made and entered into as of June 14, 2021, by and between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and Lind Global Asset Management II, LLC, a Delaware limited liability company ("Lind" and, together with the Company, the "Parties"). RECITALS WHEREAS, th |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 24, 2021 |
Exhibit 99.1 Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, May 24, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today t |
|
| May 21, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 21, 2021 |
Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403) Officer's Statement (PURSUANT TO NRS 80.030) 1. Entity information: N |
|
| May 21, 2021 |
19,354,840 Shares of Common Stock SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENT Exhibit 1.1 19,354,840 Shares of Common Stock SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENT May 20, 2021 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Seelos Therapeutics, Inc., a corporation organized and existing under the laws of the |
|
| May 21, 2021 |
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock Exhibit 99.1 Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock NEW YORK, May 20, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 |
|
| May 21, 2021 |
19,354,840 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2020) 19,354,840 Shares of Common Stock We are offering 19,354,840 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol "SEEL." On May 19, 2021, the last reported sale price of our common stock on the Nasdaq Capital Ma |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 19, 2021 |
SUBJECT TO COMPLETION, DATED MAY 19, 2021 Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| May 17, 2021 |
Exhibit 99.1 Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine), Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder -SLS-002 Demonstrated a 76.5% Response Rate in the Primary Endpoint on MADRS 24 Hours After First Dose |
|
| May 17, 2021 | ||
| May 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 30, 2021 |
As filed with the Securities and Exchange Commission on April 30, 2021 Registration No. |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEELOS T |
|
| April 30, 2021 |
SEELOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (EFFECTIVE APRIL 1, 2021) Exhibit 10.2 SEELOS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (EFFECTIVE APRIL 1, 2021) Non-employee members of the board of directors (the "Board") of Seelos Therapeutics, Inc. (the "Company") shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy. The cash compensation and option grants described in this Non-Emp |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 12, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 1, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 000-22245 SEELOS THERAPEUTICS, INC |
|
| February 18, 2021 |
AMENDMENT NO. 4 TO ASSET PURCHASE AGREEMENT Exhibit 10.1 ***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets ("[...***...]") in this exhibit. *** AMENDMENT NO. 4 TO ASSET PURCHASE AGREEMENT This Amendment No. 4 (this "Amendment") to the Asset Purchase Agr |
|
| February 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2021 Seelos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 000-22245 87-0449967 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 18, 2021 |
February 15, 2021 8-K Exhibit 99.1 Exhibit 99.1 Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program) NEW YORK, Feb. 18, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system d |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Seelos Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 81577F109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| January 28, 2021 |
Financial Statements and Exhibits, Other Events - 8-K January 28, 2021 8K DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 28, 2021 |
January 28, 2021 8-K Exhibit 99.1 Exhibit 99.1 Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares NEW YORK, January 28, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and |
|
| January 26, 2021 |
15,243,903 Shares of Common Stock January 25, 2021 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 PROSPECTUS SUPPLEMENT (to Prospectus dated December 23, 2020) 15,243,903 Shares of Common Stock We are offering 15,243,903 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol "SEEL." On January 25, 2021, the last reported sale price of our common sto |
|
| January 26, 2021 |
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock January 26, 2021 8-K Exhibit 99.1 Exhibit 99.1 Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock NEW YORK, January 26, 2021 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwri |
|
| January 26, 2021 |
15,243,903 Shares SEELOS THERAPEUTICS, Inc. Common Stock January 26, 2021 8-K Exhibit 1.1 Exhibit 1.1 15,243,903 Shares SEELOS THERAPEUTICS, Inc. Common Stock UNDERWRITING AGREEMENT January 25, 2021 BTIG, LLC 600 Montgomery Street San Francisco, California 94111 Ladies and Gentlemen: 1. INTRODUCTORY. Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), proposes to sell, pursuant to the terms of this Agreement, to BTIG, LLC (the "Underwriter" |
|
| January 26, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K January 26, 2021 8K DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 25, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 25, 2021 January 25, 2021 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-251356 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell t |
|
| January 15, 2021 |
SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Seelos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 81577F109 (CUSIP |
|
| January 12, 2021 |
January 12, 2021 8K DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ** UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Seelos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 81577F109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| December 22, 2020 |
December 22, 2020 S-3A DOC As filed with the Securities and Exchange Commission on December 22, 2020 Registration No. |
|
| December 22, 2020 |
Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York, NY 10022 Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York, NY 10022 December 22, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-3, Initially Filed December 15, 2020 Registration No. 333-251356 Ladies and Gentlemen: Pursuant to Rule 461 |
|
| December 17, 2020 |
December 17, 2020 8-K Exhibit 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this "Agreement") is entered into as of December 11, 2020, by and between Seelos Therapeutics, Inc., a Nevada corporation (the "Company"), and Lind Global Asset Management II, LLC, a Delaware limited liability compan |
|
| December 17, 2020 |
December 17, 2020 8-K Exhibit 10.2 Exhibit 10.2 SECURITY AGREEMENT SECURITY AGREEMENT (this "Agreement"), dated as of December 11, 2020, by and between SEELOS THERAPEUTICS, INC., a Nevada corporation (the "Company") and LIND GLOBAL ASSET MANAGEMENT II, LLC (the "Secured Party"). WHEREAS, the Company (a) and the Secured Party have entered into that certain Securities Purchase Agreement dated as of |
|
| December 17, 2020 |
December 17, 2020 8K DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 17, 2020 |
December 17, 2020 8-K Exhibit 4.1 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PUR |
|
| December 15, 2020 |
December 15, 2020 S-3 DOC As filed with the Securities and Exchange Commission on December 15, 2020 Registration No. |
|
| December 15, 2020 |
SEELOS THERAPEUTICS, INC., Issuer [TRUSTEE], Trustee Dated as of , 20 Debt Securities December 15, 2020 S-3 Exhibit 4.23 Exhibit 4.23 SEELOS THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securit |
|
| December 14, 2020 |
Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note December 14, 2020 8-K Exhibit 99.1 Exhibit 99.1 Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note NEW YORK, Dec. 14, 2020 /PRNewswire/ - Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the sale of a $12.0 m |
|
| December 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K December 14, 2020 8K DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 4, 2020 |
December 4, 2020 424(b)(3) Filed Pursuant to Rule 424(b)(3) Registration No. 333-250810 PROSPECTUS 6,648,750 Shares Common Stock This prospectus relates to the resale by the investors listed in the section of this prospectus entitled "Selling Stockholders" (the "Selling Stockholders"), of up to 6,648,750 shares (the "Shares") of our common stock, par value $0.001 per share ("Common Stock"). The 6, |
|
| December 2, 2020 |
Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York, NY 10022 December 2, 2020 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Seelos Therapeutics, Inc. Registration Statement on Form S-1, Filed November 20, 2020 File No. 333-250810 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Seelos Therapeutics, |
|
| November 20, 2020 |
November 20, 2020 S-1 DOC As filed with the Securities and Exchange Commission on November 20, 2020 Registration No. |
